Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus.

ABSTRACT:

Background

Bexagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. A pilot study has shown that bexagliflozin can decrease dependence on exogenous insulin in cats with diabetes mellitus (DM).

Objective

To evaluate the safety and effectiveness of bexagliflozin as a monotherapy for DM in previously untreated cats.

Animals

Eighty-four client-owned cats.

Methods

Historically controlled prospective open-label clinical trial. Cats were dosed PO with 15 mg bexagliflozin once daily for 56 days, with a 124-day extension to evaluate safety and treatment effect durability. The primary endpoint was the proportion of cats experiencing a decrease in hyperglycemia and improvement in clinical signs of hyperglycemia from baseline on day 56.

Results

Of 84 enr

SUBMITTER: Hadd MJ 

PROVIDER: S-EPMC10229323 | biostudies-literature | 2023 May-Jun

REPOSITORIES: biostudies-literature